AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05169710
Drug: SEP-4199 CR 400 mg
RxNorm normalized name: atropine sulfate / benzoic acid / hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate Oral Tablet [Uri-Sep]
DrugBank: Hyoscyamine (DB00424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEP-4199 CR 400 mg tablet (supplied in two 200mg tablets)
Trial: NCT05342844
Drug: Dexmedetomidine 0.5 mcg
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5 mcg/kg
Trial: NCT05342844
Drug: Dexmedetomidine 1 mcg
RxNorm normalized name: dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mcg/kg
Trial: NCT04962022
Drug: PF-07321332/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3
Trial: NCT04962022
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally once daily for 8 days from Days 1 through 8
Trial: NCT04962022
Drug: PF-07321332/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally BID for 3 day for a total on 5 doses starting on Day 4 through Day 6
Trial: NCT06443151
Drug: Sodium Nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Endothelium-independent vasodilation will be assessed by changes in forearm blood flow in response to intra-arterial infusions of sodium nitroprusside at 1.0, 2.0, 4.0 μg/100 mL forearm tissue/min.
Trial: NCT01868048
Drug: Sativex
RxNorm normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.~Subjects receive study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
Trial: NCT04854837
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remdesivir treatment
Trial: NCT06558708
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once daily
Trial: NCT06128460
Drug: Zimberelimab
RxNorm normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240mg, q3w，8 cycles
Trial: NCT06128460
Drug: Platinum
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin 40mg/m2 for 5-6 cycles
Trial: NCT04639180
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive Camrelizumab intravenously, Dosage form: lyophilized powder
Trial: NCT04639180
Drug: Rivoceranib (Apatinib)
RxNorm normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive Rivoceranib (Apatinib) orally, Dosage form: tablet
Trial: NCT05458076
Drug: QLS1128 A-Dose 1~5 and Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cohort 1:~QLS1128 A-Dose 1 or Placebo~Cohort 2:~Period 1: QLS1128 A-Dose 2 or Placebo, on day 1. Period 2:QLS1128 A-Dose 2 or Placebo with high fat meal on day 5. Period 3:QLS1128 A-Dose 2 or Placebo plus Ritonavir on day 9~Cohort 3:~QLS1128 A-Dose 3 or Placebo~Cohort 4:~QLS1128 A-Dose 4 or Placebo~Cohort 5:~QLS1128 A-Dose 5 or Placebo
Trial: NCT05458076
Drug: QLS1128 C-Dose 1~3 and Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cohort 6:~Period 1: QLS1128 C-Dose 1 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 1 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 7:~Period 1: QLS1128 C-Dose 2 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 2 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 8:~Period 1: QLS1128 C-Dose 3 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 3 or Placebo plus Ritonavir , twice daily for 7 days
Trial: NCT05458076
Drug: QLS1128 D-Dose 1 and Ritonavir
RxNorm normalized name: lopinavir and ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cohort 9:~Group A:QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 1. QLS1128 D-Dose 1 plus Ritonavir under fatty food condition, on day 5~Group B: QLS1128 D-Dose 1 plus Ritonavir under fatty food condition , on day 1. QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 5
Trial: NCT04952064
Drug: Monosialoganglioside GM1
RxNorm normalized name: Monosialoganglioside GM1 antibody
DrugBank: Ganglioside GM1 (DB16948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monosialoganglioside GM1 diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
Trial: NCT05168735
Drug: Intravenous Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
Trial: NCT04360070
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral General Anesthetic
Trial: NCT03723083
Drug: CC-2001
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-2001 will be administered orally
Trial: NCT06168214
Drug: Vonoprazan+amoxicillin+furazolidone 7 days
RxNorm normalized name: AMOXICILLIN/VONOPRAZAN
DrugBank: Furazolidone (DB00614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hVAF: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; F: furazolidone 100mg bid.
Trial: NCT06168214
Drug: Vonoprazan+amoxicillin 7 days
RxNorm normalized name: AMOXICILLIN/VONOPRAZAN
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hVA7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
Trial: NCT06168214
Drug: Vonoprazan+amoxicillin 14 days
RxNorm normalized name: vonoprazan
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: hVA14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
Trial: NCT05441904
Drug: PXL770
RxNorm normalized name: PXL770 free acid anhydrous
DrugBank: PXL-770 free acid anhydrous (DB17615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 500 and 750 mg was administered to each subject.
Trial: NCT00002152
Drug: WF10
RxNorm normalized name: Sodium hypochlorite
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06216639
Drug: Bismuth Subcitrate
RxNorm normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tripotassium dicitratobismuthate 120 mg film-coated tablets. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 120 mg QID for a period of 14 days.
Trial: NCT06216639
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazol 40 mg gastro-resistant tablets or hard capsules. Which one of the three brands is prescribed for an individual participant in this prospective study depends on the decision of a chosen personal physician. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 40 mg BID for a period of 14 days.
Trial: NCT06216639
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazol 400 mg tablets. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 400 mg QID for a period of 14 days.
Trial: NCT06216639
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 500 mg dispersible tablets or hard capsules. Which one of the two brands is prescribed for an individual participant in this prospective study depends on the decision of a chosen personal physician. Prescribed only for the primary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection who are not allergic to penicillin. The prescribed daily dose is 500 mg QID for a period of 14 days.
Trial: NCT06216639
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg film-coated tablets. Prescribed only for the (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 500 mg OID for a period of 14 days.
Trial: NCT04543643
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As the third generation of NSBB, carvedilol is more effective in reducing HVPG than propranolol, which is recommended by Baveno VI as the first-line drug for EVB primary prevention.
Trial: NCT04543643
Drug: Berberine
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine can regulate the intestinal flora, which is safe and effective in clinical application.
Trial: NCT06187441
Drug: Daratumumab Injection
RxNorm normalized name: daratumumab Injection
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
Trial: NCT06187441
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
Trial: NCT06187441
Drug: Lenalidomide capsule
RxNorm normalized name: Lenalidomide Capsules
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
Trial: NCT06009874
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: patients will be treated with DAPA 10 mg once daily for three months
Trial: NCT05884320
Drug: Sacituzumab Govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT05187208
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib 200mg or 300mg (once daily \[QD\])\*~\*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD.
Trial: NCT03537807
Drug: Riluzole
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For adult patients, one 40mg of BHV-0223, administered sublingually, on a twice daily basis (approximately every 12 hours).
Trial: NCT06383273
Drug: Midalozam sublingual tablet
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each dose of midazolam will be provided as a single sublingual tablet, containing 3 mg midazolam. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
Trial: NCT03593252
Drug: Senna
RxNorm normalized name: Senna
DrugBank: Senna leaf (DB15889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxative,used for bowel preparation
Trial: NCT03593252
Drug: Metronidazole Oral
RxNorm normalized name: metronidazole Oral Gel
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral antibiotic
Trial: NCT03593252
Drug: Neomycin
RxNorm normalized name: Neomycin
DrugBank: Neomycin (DB00994)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral non-absorbable antibiotic
Trial: NCT03593252
Drug: Cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotic to be given on anesthesia induction and prior to incision as a prophylactic antibiotic.
Trial: NCT03593252
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotic to be given on anesthesia induction and prior to incision as prophylactic antibiotic.
Trial: NCT05590286
Drug: Vonoprazan Tablets
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vonoprazan 20 mg, tablets, orally，QD
Trial: NCT05590286
Drug: Amoxicillin Capsules
RxNorm normalized name: Amoxicillin Capsules
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 750mg, Capsules ,orally，QID
Trial: NCT05590286
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20mg, Capsules ,orally，BID
Trial: NCT06413186
Drug: Uteratonic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administer IV 10 IU oxytocin
Trial: NCT05376228
Drug: Oral Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As part of standard of care
Trial: NCT06534450
Drug: IVIG
RxNorm normalized name: hIVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Immunoglobulin
Trial: NCT04002011
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It will be started on postoperative day 1 or later when oral anticoagulation is secondary indicated. Daily dose will be adapted to obtain an international normalized ratio of \[2.0-3.0\]. Other anticoagulants will be not administrated.
Trial: NCT04002011
Drug: Dabigatran
RxNorm normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
Trial: NCT06371807
Drug: Pembrolizumab injection
RxNorm normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: (KXCb - PA\[E\]C) vs (KPA\[E\]C - KXCb) Pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab in the adjuvant setting vs Pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab in the adjuvant setting
Trial: NCT05567796
Drug: Cagrilintide
RxNorm normalized name: Cagrilintide
DrugBank: Cagrilintide (DB18887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cagrilintide will be administered subcutaneously.
Trial: NCT05567796
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will recieve semaglutide subcutaneously.
Trial: NCT04002011
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
Trial: NCT04002011
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
Trial: NCT04002011
Drug: Edoxaban
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
Trial: NCT06223932
Drug: Molnupiravir
RxNorm normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: COVID-19 diagnosed patients receiving molnupiravir will be evaluated to show if Molnupiravir is effective in reducing the combined outcome of hospitalization/death due to COVID-19 in the first 28 days when used in real life.
Trial: NCT00086203
Drug: Talabostat mesylate (PT-100) tablets
RxNorm normalized name: delavirdine
DrugBank: Talabostat (DB06182)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00086203
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02239276
Drug: Stiripentol
RxNorm normalized name: Stiripentol
DrugBank: Stiripentol (DB09118)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The initial dose of Stiripentol will be determined by the prescribing neurologist and titrated up to an initial goal dose of 50 mg/kg/day divided into 2 to 3 doses per day. Further dose increases by 10-20 mg/kg/day increments up to a max of 100 mg/kg/day or 4000 mg total daily dose may be necessary for improved seizure control.
Trial: NCT05571787
Drug: Rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg of rabeprazole will be administered by mouth once daily in the morning from Day 20 to Day 26
Trial: NCT01523379
Drug: Parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 90mg Parecoxib i.v. two times a day, two days in a row
Trial: NCT05572281
Drug: Tasimelteon Oral Capsule
RxNorm normalized name: tasimelteon Oral Capsule
DrugBank: Tasimelteon (DB09071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No additional information
Trial: NCT05572281
Drug: Tasimelteon Oral Suspension
RxNorm normalized name: tasimelteon Oral Suspension
DrugBank: Tasimelteon (DB09071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No additional information
Trial: NCT05754840
Drug: MPL-001
RxNorm normalized name: MPL
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-CBD arm (MPL-001) a cannabidiol-enriched cannabis herbal extract which contains a 1:25 ratio of THC:CBD. The MPL-001 oil is produced by MediPharm Labs, each ml contains 50mg CBD and 2mg THC.
Trial: NCT05754840
Drug: MPL-005
RxNorm normalized name: MPL
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-CBD arm (MPL-005) a cannabidiol-enriched cannabis herbal extract which contains a 1:5 ratio of THC:CBD. The MPL-005 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 5mg THC.
Trial: NCT05754840
Drug: MPL-009
RxNorm normalized name: MPL
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced arm (MPL-009) a balanced 1:1 ratio of THC:CBD. The MPL-009 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 25mg THC.
Trial: NCT05679024
Drug: Apixaban 2.5 milligram Oral Tablet
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Tablet
Trial: NCT05013463
Drug: Hydroxychloroquine Pill
RxNorm normalized name: hydroxychloroquine Pill
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Hydroxychloroquine, 200mg BID
Trial: NCT04596475
Drug: glecaprevir/pibrentasvir (GLE/PIB)
DrugBank: Pibrentasvir (DB13878)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The study intervention consists of a single daily dose of GLE/PIB 100/40 mg (one dose consists of 3 tablets) administered orally; or crushed and administered via a feeding tube if participant is unable to swallow by mouth, for example in the immediate post-operative period. First dose will be administered in the pre-operative period within 4 hours of surgery followed by once daily doses for 7 days total.
Trial: NCT05974280
Drug: Alofisel
DrugBank: Darvadstrocel (DB16581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alofisel is made up of 'mesenchymal stem cells' from the fat tissue of a donor. Alofisel is a medicine that is used to treat complex anal fistulas in adults with Crohn's disease
Trial: NCT05974280
Drug: Fat stem cell
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesenchymal stem cells from adipose (fat) tissue injection
Trial: NCT05827991
Drug: 5% minoxidil external use
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The method of use of 5% minoxidil tincture is for topical use on the scalp, 1 ml per time, 2 times per day.
Trial: NCT05952544
Drug: essential amino acids and keto-analogues supplementation
RxNorm normalized name: Keto-C
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: very low protein diet plus essential amino acids and keto-analogues supplementation
Trial: NCT04882163
Drug: CC-220
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-220
Trial: NCT04882163
Drug: Polatuzumab vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin